A technical reference for licensed practitioners on Modified Cross-Linking Poly-Ether — the process that controls BDDE attachment sites, produces biphasic gel cohesivity, and delivers batch-consistent elastic modulus across the Sofiderm Refine range.
MCLPE — Modified Cross-Linking Poly-Ether — is Sofiderm’s proprietary HA stabilisation process. Like all contemporary HA fillers, it uses BDDE (1,4-butanediol diglycidyl ether) as the cross-linking agent. What makes MCLPE distinct is the mechanism of reaction control: BDDE is constrained to bond only at unreacted hydroxyl sites along the HA chain, rather than reacting indiscriminately with multiple positions.
Standard BDDE cross-linking produces heterogeneous networks — some chain segments are heavily cross-linked, others barely connected. MCLPE’s site-selective chemistry produces a denser yet more evenly distributed cross-link matrix, which translates directly into biphasic gel cohesivity: the gel behaves as a cohesive elastic solid under static load, and returns to its original shape after dynamic deformation.
A critical consequence of this precision is residual BDDE below 2 ppm — well within EU safety thresholds. Because BDDE reacts more completely and selectively, less unreacted cross-linker remains in the final product. The result is a gel that is both structurally superior and chemically cleaner than what conventional manufacturing achieves.
Five key parameters that differentiate Sofiderm’s process from conventional BDDE cross-linking methods used across the industry.
| Property | MCLPE — Sofiderm | Standard BDDE |
|---|---|---|
| Residual cross-linker | < 2 ppm (confirmed) | 2 – 8 ppm typical; variable by batch |
| Gel network uniformity | Homogeneous — site-selective bonding | Heterogeneous — random multi-site attachment |
| G′ (elastic modulus) predictability | Consistent batch-to-batch (≤ 5% deviation) | Variable — cross-link density affects G′ proportionally |
| Tissue integration | Biphasic cohesivity — natural deformation under movement | Monophasic — can feel rigid or fragmented at injection site |
| Batch consistency | ISO 13485-controlled; QC-gated per lot | Depends on manufacturer QC discipline |
The chemistry directly determines what a practitioner experiences at the needle and what the patient experiences over time. Three areas where MCLPE precision makes a measurable difference.
Consistent G′ across batches means the gel’s elastic response is what the specification states. Practitioners can plan lift depth and projection with confidence that the product in vial 12 performs identically to vial 1 — not something true of all manufacturers.
Homogeneous cross-link networks produce predictable extrusion force through the needle. Practitioners encounter the same back-pressure regardless of lot number, which translates to better volumetric control and reduced technique variability.
Residual BDDE below 2 ppm means fewer exogenous chemical residues at the injection site post-implantation. Lower chemical load correlates with reduced local inflammatory response, faster resolution of injection-site reactions, and a biocompatibility profile that aligns with the expectations of European practitioners under MDR 2017/745.
MCLPE applies to cross-linked formulations only. The Revitalize and Enhance ranges serve different clinical roles and are manufactured differently.
All five Refine variants use MCLPE processing. BDDE is the cross-linker; site-selective attachment delivers uniform G′ values calibrated for each depth and indication. From superficial fine-line correction to deep volumisation and body contouring.
Non-cross-linked free-chain HA skin boosters. MCLPE does not apply to this range — the mechanism of action is hydration and tissue remodelling rather than structural volumisation. Not currently available to order.
Meso-therapy formulations combining HA with active ingredients (vitamins, peptides, amino acids). Non-cross-linked; MCLPE does not apply. Targets skin quality and regeneration rather than structural correction. Not currently available to order.
Questions practitioners ask most often about MCLPE, BDDE, and Sofiderm cross-linking chemistry.
MCLPE stands for Modified Cross-Linking Poly-Ether. It is Sofiderm’s proprietary manufacturing process that controls the precise sites at which BDDE (1,4-butanediol diglycidyl ether) bonds to the hyaluronic acid chain — exclusively targeting unreacted hydroxyl groups. This site-selectivity produces a more uniform gel network and limits the amount of residual cross-linker in the final product.
Standard BDDE cross-linking allows the cross-linker to react with multiple HA chain sites in an uncontrolled manner, producing heterogeneous gel networks with variable residual BDDE and inconsistent G′ values between batches. MCLPE constrains BDDE attachment to unreacted hydroxyl sites only, resulting in a denser but more uniform network, residual BDDE below 2 ppm (well under EU safety thresholds), and consistent elastic modulus values batch-to-batch.
Sofiderm MCLPE-processed fillers contain residual BDDE below 2 ppm. The EU safety threshold for BDDE in HA dermal fillers is generally cited at 2 ppm or below as the acceptable limit. Sofiderm products are manufactured to achieve values well within this boundary, confirmed by independent batch testing under ISO 13485 quality controls.
Yes. The more uniform gel network produced by MCLPE provides biphasic cohesivity — the gel is firm enough to resist tissue compression (maintaining lift) while remaining pliable enough to deform naturally with movement. Lower residual cross-linker content also means fewer exogenous chemical residues at the injection site, which correlates with improved biocompatibility profiles in clinical use.
All products in the Sofiderm Refine family — Finelines, Derm, Deep, Volume, and Sub-Skin — use MCLPE cross-linking. The Revitalize skin booster range is non-cross-linked (free HA) and does not apply MCLPE processing. The Enhance meso-complex range is also non-cross-linked and delivers active ingredients rather than volumising HA gel.
Review the full Sofiderm Refine range with technical specifications, or register your clinic to access professional pricing and clinical support across Portugal and Spain.